TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19586154

Group type: EXPERIMENTAL
Intervention: Baseline scores of the situational temptations inventory
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Positive/social temptation subscore
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Fagerstrom test of nicotine dependence
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Stages of change
Number of subjects: 577
Study: 17605483

Group type: EXPERIMENTAL
Intervention: External bleaching treatment (bleaching gel for 60 minutes, followed by in-office bleaching and 2-week home bleaching for 1 hour daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Questionnaire on patient satisfaction
Number of subjects: 10
Study: 15843228

Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone (100 mg loading dose followed by continuous infusion of 0.18 mg/kg/h for 6 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone
Number of subjects: 24
Study: 12028309

Group type: EXPERIMENTAL
Intervention: Electrosurgical pulpotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Formocresol pulpotomy
Number of subjects: 50
Study: 9457193

Group type: EXPERIMENTAL
Intervention: Arrow-Trerotola percutaneous thrombolytic device (PTD)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Pulse-spray pharmacomechanical thrombolysis (PSPMT)
Number of subjects: 122
Study: 7823364

Group type: EXPERIMENTAL
Intervention: Topical rhPDGF‐BB (2.2 micrograms/cm2 of ulcer area)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Topical rhPDGF‐BB
Number of subjects: 118

Group type: COMPARATOR
Intervention: Topical rhPDGF‐BB and Placebo
Number of subjects: 118
Study: 2248812

Group type: EXPERIMENTAL
Intervention: i.m. ketorolac trometamol 30 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: morphine sulphate 10 mg
Number of subjects: 100
Study: 7309298

Group type: EXPERIMENTAL
Intervention: SROC 160 (160 mg oxprenolol slow-release + 20 mg chlorthalidone once daily)
Number of subjects: 103

Group type: COMPARATOR
Intervention: COC 80 (80 mg oxprenolol + 10 mg chlorthalidone twice daily)
Number of subjects: 103
Study: 30657033

Group type: EXPERIMENTAL
Intervention: C. spinosa oxymel (10 mL/thrice daily for 3 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: C. spinosa oxymel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simple oxymel
Number of subjects: 30
Study: 29102985

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided real GN pulsed radiofrequency
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ultrasound-guided sham GN pulsed radiofrequency (placebo)
Number of subjects: 142
Study: 26238226

Group type: EXPERIMENTAL
Intervention: NYU Caregiver Intervention for Adult Children (NYUCI‐AC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 107
Study: 24158337

Group type: EXPERIMENTAL
Intervention: Group IM (immediately loaded implants)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group NL (nonloaded implants)
Number of subjects: 40
Study: 22087576

Group type: EXPERIMENTAL
Intervention: Squat training with whole-body vibration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Squat training without vibration
Number of subjects: 23
Study: 19178789

Group type: EXPERIMENTAL
Intervention: High-fat rice pudding
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-carbohydrate rice pudding
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Taste condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Basal condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fullness condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Distraction condition
Number of subjects: 40
Study: 17989948

Group type: EXPERIMENTAL
Intervention: Hydrosome wound gel
Number of subjects: 47

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 47
Study: 15086213

Group type: EXPERIMENTAL
Intervention: octreotide 200 microg tid
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: octreotide 500 microg tid
Number of subjects: 36
Study: 11265037

Group type: EXPERIMENTAL
Intervention: RAB-plate
Number of subjects: 218

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 218
Study: 9590459

Group type: EXPERIMENTAL
Intervention: Sparse sampling method (7 blood samples)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Limited sampling model (LSM) using samples from 10 subjects at 6 and 8 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sparse sampling method
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Limited sampling model (LSM)
Number of subjects: 50
Study: 7834260

Group type: EXPERIMENTAL
Intervention: High-frequency electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unilateral ECT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral ECT
Number of subjects: 0
Study: 3605315

Group type: EXPERIMENTAL
Intervention: GCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: GCS‐O/O
Number of subjects: 12

Group type: COMPARATOR
Intervention: NO‐GCS
Number of subjects: 12
Study: 28581366

Group type: EXPERIMENTAL
Intervention: Lying-flat positioning
Number of subjects: 94

Group type: COMPARATOR
Intervention: Upright head positioning
Number of subjects: 94

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 94
Study: 28233128

Group type: EXPERIMENTAL
Intervention: 1210-nm laser treatment on one breast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (untreated breast)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1210-nm laser treatment
Number of subjects: 40
Study: 25540029

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L index score
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 289

Group type: COMPARATOR
Intervention: EQ-5D-3L index score
Number of subjects: 289
Study: 22281786

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily (Group A, 30 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg every other day (Group B, 30 patients)
Number of subjects: 60
Study: 20585269

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Shapedown (control)
Number of subjects: 49
Study: 17354119

Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg, oral)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg, oral)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16297033

Group type: EXPERIMENTAL
Intervention: Jaw and tongue movements
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hand extension
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lateral movement
Number of subjects: 10
Study: 12084605

Group type: EXPERIMENTAL
Intervention: Omapatrilat 2.5 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Omapatrilat 10 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Omapatrilat 20 mg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Omapatrilat 40 mg
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control (2.5 mg)
Number of subjects: 369
Study: 9470006

Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 88

Group type: COMPARATOR
Intervention: Milk preparation (skimmed milk enriched with oleic acid)
Number of subjects: 88
Study: 8592957

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI; n = 8)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI; n = 7)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (CON; n = 11)
Number of subjects: 26
Study: 2650517

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg/2 minutes followed by 0.35 mg/kg/2 minutes if needed)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem after placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 113
Study: 410740

Group type: EXPERIMENTAL
Intervention: Tolmetin and glibenclamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31539075

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents
Number of subjects: 4289

Group type: EXPERIMENTAL
Intervention: Anti-epidermal growth factor receptor agents
Number of subjects: 4289
Study: 30591684

Group type: COMPARATOR
Intervention: Normal eating rate (6 min for 600 kcal meal)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Slow eating rate (24 min for 600 kcal meal)
Number of subjects: 21
Study: 26481267

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) simulation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional cadaveric dissection training
Number of subjects: 40
Study: 24489841

Group type: EXPERIMENTAL
Intervention: Community-level intervention designed to increase testing and lower HIV incidence
Number of subjects: 657
Study: 22987084

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Control (no trastuzumab)
Number of subjects: 1830
Study: 19804445

Group type: EXPERIMENTAL
Intervention: Temperature modulation on histamine stimulus (32 degrees C to 25 degrees C) in lesional skin (LS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Temperature modulation on histamine stimulus (32 degrees C to 25 degrees C) in nonlesional skin (NLS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy skin (HS) of age-matched volunteers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Functional MRI analysis during itch provocation in NLS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Functional MRI analysis during itch provocation in LS
Number of subjects: 22
Study: 17656284

Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF) screw
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intermaxillary fixation (IMF) screw
Number of subjects: 40
Study: 16084050

Group type: EXPERIMENTAL
Intervention: Rolimeter knee tester
Number of subjects: 30
Study: 12230317

Group type: EXPERIMENTAL
Intervention: Diet habitually high in fresh fruits and vegetables, modest in calories and alcohol, and low in red meat and animal fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium, folate, and selenium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytochemicals (plant-based compounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensible amount of calories and maintaining a desirable weight
Number of subjects: 0
Study: 10436712

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 106
Study: 8522641

Group type: EXPERIMENTAL
Intervention: Single 50 mg, 100 mg, and 200 mg oral doses of nefazodone hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Twice daily doses of 50 mg, 100 mg, and 200 mg of nefazodone hydrochloride for 7.5 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nefazodone hydrochloride
Number of subjects: 18
Study: 2224266

Group type: EXPERIMENTAL
Intervention: Positive suggestions tape
Number of subjects: 63

Group type: COMPARATOR
Intervention: Blank tape
Number of subjects: 63
Study: 231594

Group type: EXPERIMENTAL
Intervention: BCNU, radiation, and hydroxyurea (HU) on alternate days during radiation (BHR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCNU and radiation (BR)
Number of subjects: 0
Study: 30085251

Group type: EXPERIMENTAL
Intervention: Plasma potassium (K+) levels
Number of subjects: 831760
Study: 28452101

Group type: EXPERIMENTAL
Intervention: Combined low-dose spironolactone plus vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E monotherapy
Number of subjects: 0
Study: 25824210

Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg in tablet form with a high-fat meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Posaconazole 300 mg in tablet form in fasted state
Number of subjects: 18

Group type: COMPARATOR
Intervention: Posaconazole oral suspension with a high-fat meal
Number of subjects: 18
Study: 23720786

Group type: EXPERIMENTAL
Intervention: GH treatment (0.05 mg/kg recombinant human GH daily)
Number of subjects: 73
Study: 22143218

Group type: EXPERIMENTAL
Intervention: Group Counseling Integration Program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study: 19017878

Group type: EXPERIMENTAL
Intervention: Therapeutic Pneumatic Compression Devices (PCDs)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham Devices
Number of subjects: 35
Study: 18072840

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (three 1-hr counseling sessions plus 8 weeks of nicotine patch therapy)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Brief smoking cessation intervention (15-min counseling session with 5 min of follow-up)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Brief smoking cessation intervention
Number of subjects: 118
Study: 16294460

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.25 mg TMG
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.125 mg TMG
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: 1 mg E2V/1 mg NET
Number of subjects: 1218
Study: 12478329

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily
Number of subjects: 404

Group type: COMPARATOR
Intervention: Amoxicillin 1,000 mg three times a day
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Telithromycin (subset analysis)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Amoxicillin (subset analysis)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 404

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 404
Study: 9890248

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nonteratogenic antibiotics (Control)
Number of subjects: 157
Study: 7654891

Group type: COMPARATOR
Intervention: Ranitidine 150 mg daily
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg daily
Number of subjects: 489
Study: 2478340

Group type: EXPERIMENTAL
Intervention: 53.3 g albumin as part of blood replacement therapy, followed by 20 g albumin daily for the first three postoperative days
Number of subjects: 18

Group type: COMPARATOR
Intervention: No albumin
Number of subjects: 18
Study: 786001

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31881232

Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy (OIT)
Number of subjects: 0
Study: 31370717

Group type: EXPERIMENTAL
Intervention: Whey protein (ProLYOtin; arm A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (arm B)
Number of subjects: 47
Study: 29135370

Group type: EXPERIMENTAL
Intervention: Adjusted dose of Ribavirin (ADJ)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard dose of Ribavirin (STD)
Number of subjects: 181
Study: 25938474

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 450

Group type: COMPARATOR
Intervention: Daily oral antipsychotics
Number of subjects: 450
Study: 24156203

Group type: EXPERIMENTAL
Intervention: Potassium nitrate dentifrice
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 8.0% arginine with calcium carbonate dentifrice
Number of subjects: 212

Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 212
Study: 21613498

Group type: EXPERIMENTAL
Intervention: Tactile-auditory sensory substitution training over 5 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tactile-auditory sensory substitution training
Number of subjects: 9
Study: 20115934

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antidiabetic treatment
Number of subjects: 0
Study: 16925888

Group type: EXPERIMENTAL
Intervention: PA$$ (promotional activities and financial support)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PA (promotional activities)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison between PA$$ and PA
Number of subjects: 150
Study: 14760265

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with wheal size <5 mm
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with wheal size >=5 mm
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Milk-specific IgE <2 kU/L
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Milk-specific IgE >=2 kU/L
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Delayed reactions to cow's milk
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Immediate reactions to cow's milk
Number of subjects: 162
Study: 11728609

Group type: EXPERIMENTAL
Intervention: Pathological Gambling Disorder (PGD)
Number of subjects: 114
Study: 9224847

Group type: EXPERIMENTAL
Intervention: Static Closed Loop (SCL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full Open Loop (FOL)
Number of subjects: 0
Study: 7970937

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) administration (1 microgram/kg i.v. bolus)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metyrapone administration (450 mg/m2/dose every 4 h x seven doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metyrapone administration
Number of subjects: 16
Study: 3301758

Group type: EXPERIMENTAL
Intervention: Misonidazole (2.0 gm/m2/wk X 6 doses) with altered fractionation (2.5 Gy in a.m., 2.1 Gy in p.m.)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Misonidazole (2.0 gm/m2/wk X 6 doses)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Radiotherapy alone (control)
Number of subjects: 306
Study: 31985558

Group type: EXPERIMENTAL
Intervention: Art therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Comparison group (regular activities)
Number of subjects: 54
Study: 30313053

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg bolus followed by infusion of 5 to 15 μg/kg/min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 70
Study: 28599212

Group type: COMPARATOR
Intervention: 7.5mg THC
Number of subjects: 42

Group type: COMPARATOR
Intervention: 12.5mg THC
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0mg THC (Placebo)
Number of subjects: 42
Study: 25620378

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24155052

Group type: EXPERIMENTAL
Intervention: Individual placement and support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20923446

Group type: EXPERIMENTAL
Intervention: Topical Aloe vera (AV) 0.4 ml (70% concentration) three times a day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Topical Aloe vera (AV)
Number of subjects: 64
Study: 18421055

Group type: EXPERIMENTAL
Intervention: Self-reported social functioning (measured using EORTC QLQ-C30)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (AP)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Number of metastatic sites
Number of subjects: 564
Study: 17260222

Group type: EXPERIMENTAL
Intervention: Regime A: 400 microg of intravaginal misoprostol every 3 h
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Regime B: loading dose of 600 microg, followed by 200 microg every 3 h
Number of subjects: 138
Study: 14659328

Group type: EXPERIMENTAL
Intervention: epirubicin/vinorelbine and sequential paclitaxel (EV/T)
Number of subjects: 54

Group type: COMPARATOR
Intervention: epirubicin/cyclophosphamide plus sequential paclitaxel (EC/T)
Number of subjects: 54

Group type: COMPARATOR
Intervention: epirubicin/vinorelbine (EV)
Number of subjects: 54

Group type: COMPARATOR
Intervention: epirubicin/cyclophosphamide (EC)
Number of subjects: 54
Study: 11265381

Group type: EXPERIMENTAL
Intervention: Partial laryngectomy with reconstruction of defects using a vascular pedicle flap of the submandibular gland
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 81
Study: 8829944

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with diamorphine (2 mg initial dose, 0.2 mg h-1 background infusion, 0.2 mg on-demand doses with a 15 min lockout)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with diamorphine
Number of subjects: 22
Study: 1449278

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 3906431

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29497279

Group type: EXPERIMENTAL
Intervention: 20 mg eletriptan HBr
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan HBr
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan HBr
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan HBr (repeated oral dose 2 h apart)
Number of subjects: 16
Study: 26856226

Group type: EXPERIMENTAL
Intervention: Edoxaban 60/30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 24281285

Group type: EXPERIMENTAL
Intervention: Manual therapy protocol (5 sessions)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Manual therapy protocol
Number of subjects: 89
Study: 22571284

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) in addition to optimised non-surgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Optimised non-surgical treatment alone
Number of subjects: 100